SRC kinase inhibitor compounds
    3.
    发明授权
    SRC kinase inhibitor compounds 失效
    SRC激酶抑制剂化合物

    公开(公告)号:US06316444B1

    公开(公告)日:2001-11-13

    申请号:US09603699

    申请日:2000-06-26

    IPC分类号: A61P3706

    摘要: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

    摘要翻译: 嘧啶化合物(式I)或其药学上可接受的盐,水合物,溶剂合物,晶体形式和单独的非对映异构体,以及包含其的药物组合物,其是酪氨酸激酶的抑制剂,因此可用于预防和治疗蛋白质 酪氨酸激酶相关疾病,例如免疫疾病,过度增殖性疾病和其中认为不适当的蛋白激酶作用发挥作用的其它疾病,例如癌症,血管生成素,动脉粥样硬化症,移植排斥反应,类风湿性关节炎和牛皮癣。